Journal article
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Abstract
BACKGROUND: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). The trial showed longer progression-free survival with osimertinib …
Authors
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B
Journal
The New England Journal of Medicine, Vol. 382, No. 1, pp. 41–50
Publisher
Massachusetts Medical Society
Publication Date
January 2, 2020
DOI
10.1056/nejmoa1913662
ISSN
0028-4793